BCL-2 Inhibitors Market: Growth Drivers and Challenges
Growth Drivers
- Rising Geriatric Population – Cutaneous T-cell lymphoma (CTCL) mainly affects older people, which necessitates the use of BCL-2 inhibitors as it has limited side effects and is considered a suitable cutaneous T-cell lymphoma (CTCL) treatment option.According to the United Nations, the number of people aged 80 and more is expected to quadruple, rising from 143 million in 2019 to 426 million in 2050.
- Growing Demand for Personalized Medicine- Bcl-2 inhibitors for cancer treatment can be a part of a personalized approach for enhancing the survival of cancer patients as it can be used to adjust an individual's genetic and molecular profile.
Challenges
- Development of Resistance - BCL-2 mutations can cause resistance to venetoclax the first-in-class BCL-2 inhibitor by lowering or blocking the small molecule inhibitor's binding affinity for the anti-apoptotic Bcl2 protein that can result in uncontrolled cell proliferation and cancer.
- Side Effects Associated with BCL-2 Inhibitors Including Nausea and Diarrhea
- High Cost Resulting in Limited Access to Novel Cancer Therapies
BCL-2 (B-cell lymphoma 2) Inhibitors Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
14.1% |
|
Base Year Market Size (2024) |
USD 2.28 billion |
|
Forecast Year Market Size (2037) |
USD 12.67 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of BCL-2 inhibitors is estimated at USD 2.55 billion.
The BCL-2 inhibitors market size was valued at USD 2.28 billion in 2024 and is likely to cross USD 12.67 billion by 2037, registering more than 14.1% CAGR during the forecast period i.e., between 2025-2037. Rising cases of Diffuse B-cell Lymphoma and growing government initiatives will drive the market growth.
North America industry is poised to account for largest revenue share of 56% by 2037, impelled by increasing product approvals in the region.
The major players in the market are Amgen Inc., Ascentage Pharma Group International, AstraZeneca Plc, Seagen Inc., Servier, AbbVie Inc., F. Hoffmann La Roche Ltd., Ipsen Pharma, Merck and Co. Inc., Novartis AG.
